

Jea Hoon Kim

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/765544/jea-hoon-kim-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

98
papers

2,569
citations

26
h-index

47
g-index

108
ext. papers

3,137
ext. citations

5.1
avg, IF

4.63
L-index

#	Paper	IF	Citations
98	Identification of Prognostic Markers of Gynecologic Cancers Utilizing Patient-Derived Xenograft Mouse Models.. <i>Cancers</i> , 2022 , 14,	6.6	5
97	Identification of a novel gene signature in second-trimester amniotic fluid for the prediction of preterm birth.. <i>Scientific Reports</i> , 2022 , 12, 3085	4.9	1
96	NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59. <i>Scientific Reports</i> , 2022 , 12,	4.9	1
95	Regulates Chemoresistance in Association With by Inhibiting Apoptosis Pathway in Patients With Cervical Cancer. <i>Cancer Genomics and Proteomics</i> , 2021 , 18, 699-713	3.3	1
94	Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer. <i>Cancer Science</i> , 2021 , 112, 5055-5067	6.9	1
93	The Combination of Transient Receptor Potential Vanilloid Type 1 (TRPV1) and Phosphatase and Tension Homolog (PTEN) is an Effective Prognostic Biomarker in Cervical Cancer. <i>International Journal of Gynecological Pathology</i> , 2021 , 40, 214-223	3.2	5
92	LC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation of EGFR signaling in immune-refractory tumor cells. <i>Autophagy</i> , 2021 , 17, 1978-1997	10.2	6
91	SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment. <i>Cancers</i> , 2021 , 13,	6.6	3
90	Modulated electro-hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial. <i>Experimental and Therapeutic Medicine</i> , 2021 , 22, 787	2.1	
89	Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 620-631	21.7	58
88	Tetraspanin 1 promotes endometriosis leading to ovarian clear cell carcinoma. <i>Molecular Oncology</i> , 2021 , 15, 987-1004	7.9	5
87	MEK/ERK signaling is a critical regulator of high-risk human papillomavirus oncogene expression revealing therapeutic targets for HPV-induced tumors. <i>PLoS Pathogens</i> , 2021 , 17, e1009216	7.6	3
86	TOM40 Inhibits Ovarian Cancer Cell Growth by Modulating Mitochondrial Function Including Intracellular ATP and ROS Levels. <i>Cancers</i> , 2020 , 12,	6.6	6
85	HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors. <i>Nature Communications</i> , 2020 , 11, 562	17.4	23
84	Prognostic Significance of Transient Receptor Potential Vanilloid Type 1 (TRPV1) and Phosphatase and Tension Homolog (PTEN) in Epithelial Ovarian Cancer. <i>Cancer Genomics and Proteomics</i> , 2020 , 17, 309-319	3.3	4
83	Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 6002-6002	2.2	54
82	CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020 , 156, 211-221	4.9	6

81	Convergence of Plasma Metabolomics and Proteomics Analysis to Discover Signatures of High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2020 , 12,	6.6	8
80	ALDH1A2 Is a Candidate Tumor Suppressor Gene in Ovarian Cancer. <i>Cancers</i> , 2019 , 11,	6.6	8
79	Loss of Both USP10 and p14ARF Protein Expression Is an Independent Prognostic Biomarker for Poor Prognosis in Patients With Epithelial Ovarian Cancer. <i>Cancer Genomics and Proteomics</i> , 2019 , 16, 553-562	3.3	11
78	Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. <i>Cancer Research and Treatment</i> , 2019 , 51, 112-118	5.2	1
77	Prognostic implication of forkhead box protein O1 (FOXO1) and paired box gene 3 (PAX3) in epithelial ovarian cancer. 2019 , 5, 61-61		
76	Prognostic implications of forkhead box protein O1 (FOXO1) and paired box 3 (PAX3) in epithelial ovarian cancer. <i>BMC Cancer</i> , 2019 , 19, 1202	4.8	7
75	Combined treatment with modulated electro-hyperthermia and an autophagy inhibitor effectively inhibit ovarian and cervical cancer growth. <i>International Journal of Hyperthermia</i> , 2019 , 36, 9-20	3.7	10
74	Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3-NANOG Axis. <i>Cancer Research</i> , 2018 , 78, 2638-2653	10.1	22
73	Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer. <i>Gynecologic Oncology</i> , 2018 , 149, 381-387	4.9	24
72	Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer. <i>British Journal of Cancer</i> , 2018 , 119, 530-537	8.7	10
71	DNA Mismatch Repair Protein Immunohistochemistry and MLH1 Promotor Methylation Testing for Practical Molecular Classification and the Prediction of Prognosis in Endometrial Cancer. <i>Cancers</i> , 2018 , 10,	6.6	8
70	Elevated expression of pancreatic adenocarcinoma upregulated factor (PAUF) is associated with poor prognosis and chemoresistance in epithelial ovarian cancer. <i>Scientific Reports</i> , 2018 , 8, 12161	4.9	4
69	A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). <i>Gynecologic Oncology</i> , 2018 , 150, 247-252	4.9	35
68	Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4098-4114	15.9	17
67	An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021). <i>Cancer Research and Treatment</i> , 2018 , 50, 195-203	5.2	30
66	Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models. <i>Cancer Research and Treatment</i> , 2018 , 50, 956-963	5.2	15
65	Current Status of Human Papillomavirus Infection and Introduction of Vaccination to the National Immunization Program in Korea: an Overview. <i>Journal of Korean Medical Science</i> , 2018 , 33, e331	4.7	7
64	Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian carcinomas. <i>Obstetrics and Gynecology Science</i> , 2018 , 61, 344-351	1.9	9

63	Human Papillomavirus 16 Oncoproteins Downregulate the Expression of miR-148a-3p, miR-190a-5p, and miR-199b-5p in Cervical Cancer. <i>BioMed Research International</i> , 2018 , 2018, 1942867	3	15
62	Establishment of five immortalized human ovarian surface epithelial cell lines via SV40 T antigen or HPV E6/E7 expression. <i>PLoS ONE</i> , 2018 , 13, e0205297	3.7	14
61	Preoperative assessment of lymph node metastasis in endometrial cancer: A Korean Gynecologic Oncology Group study. <i>Cancer</i> , 2017 , 123, 263-272	6.4	19
60	Association of isolated single umbilical artery with perinatal outcomes: Systemic review and meta-analysis. <i>Obstetrics and Gynecology Science</i> , 2017 , 60, 266-273	1.9	14
59	API5 induces cisplatin resistance through FGFR signaling in human cancer cells. <i>Experimental and Molecular Medicine</i> , 2017 , 49, e374	12.8	13
58	HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells. <i>Cancer Research</i> , 2017 , 77, 5039-5053	10.1	57
57	Bcl-2-like Protein 11 (BIM) Expression Is Associated with Favorable Prognosis for Patients with Cervical Cancer. <i>Anticancer Research</i> , 2017 , 37, 4873-4879	2.3	4
56	Diagnostic performance and establishment of reference limits of HE4 in Korean healthy women. <i>Gynecologic Oncology</i> , 2016 , 143, 128-134	4.9	5
55	Multiparametric MR imaging of tumor response to intraarterial chemotherapy in orthotopic xenograft models of human metastatic brain tumor. <i>Journal of Neuro-Oncology</i> , 2016 , 127, 243-51	4.8	7
54	Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients. <i>Journal of Translational Medicine</i> , 2016 , 14, 124	8.5	26
53	Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 49481-49497	3.3	49
52	Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 77052-77070	3.3	11
51	Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer. <i>Yonsei Medical Journal</i> , 2016 , 57, 580-7	3	12
50	Makorin Ring Finger Protein 1 as Adjunctive Marker in Liquid-based Cervical Cytology. <i>Medicine (United States)</i> , 2016 , 95, e2425	1.8	1
49	PI3K/AKT activation induces PTEN ubiquitination and destabilization accelerating tumourigenesis. <i>Nature Communications</i> , 2015 , 6, 7769	17.4	105
48	Clinical significance of OCT4 and SOX2 protein expression in cervical cancer. <i>BMC Cancer</i> , 2015 , 15, 10154.8	5.8	59
47	Prognostic Significance of AMP-Dependent Kinase Alpha Expression in Cervical Cancer. <i>Pathobiology</i> , 2015 , 82, 203-11	3.6	10
46	The Korean guideline for cervical cancer screening. <i>Journal of Gynecologic Oncology</i> , 2015 , 26, 232-9	4	37

45	Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2015 , 6, 39088-97	3.3	49
44	A phase 2 trial of radiation therapy with concurrent paclitaxel chemotherapy after surgery in patients with high-risk endometrial cancer: a Korean Gynecologic Oncologic Group study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 90, 140-6	4	2
43	Apoptosis inhibitor-5 overexpression is associated with tumor progression and poor prognosis in patients with cervical cancer. <i>BMC Cancer</i> , 2014 , 14, 545	4.8	23
42	Incorporation of pazopanib in maintenance therapy of ovarian cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3374-82	2.2	245
41	Expression of stress-induced phosphoprotein1 (STIP1) is associated with tumor progression and poor prognosis in epithelial ovarian cancer. <i>Genes Chromosomes and Cancer</i> , 2014 , 53, 277-88	5	28
40	Synaptonemal complex protein 3 is a prognostic marker in cervical cancer. <i>PLoS ONE</i> , 2014 , 9, e98712	3.7	17
39	MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer. <i>BMC Cancer</i> , 2014 , 14, 957	4.8	48
38	The role of S100A14 in epithelial ovarian tumors. <i>Oncotarget</i> , 2014 , 5, 3482-96	3.3	24
37	Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry. <i>Journal of Translational Medicine</i> , 2013 , 11, 185	8.5	45
36	Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. <i>Human Pathology</i> , 2013 , 44, 1365-74	3.7	36
35	Downregulation of ERp57 expression is associated with poor prognosis in early-stage cervical cancer. <i>Biomarkers</i> , 2013 , 18, 573-9	2.6	21
34	Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer. <i>Cancer Investigation</i> , 2013 , 31, 607-15	2.1	54
33	Clinical significance of serum anti-human papillomavirus 16 and 18 antibodies in cervical neoplasia. <i>Obstetrics and Gynecology</i> , 2013 , 121, 321-329	4.9	4
32	Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition. <i>Journal of Gynecologic Oncology</i> , 2013 , 24, 186-203	4	21
31	Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer. <i>Annals of Surgical Oncology</i> , 2012 , 19, 1707-12	3.1	34
30	Human chorionic gonadotrophin regression rate as a predictive factor of postmolar gestational trophoblastic neoplasm in high-risk hydatidiform mole: a case-control study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2012 , 160, 100-5	2.4	10
29	Prevalence and seroprevalence of low-risk human papillomavirus in Korean women. <i>Journal of Korean Medical Science</i> , 2012 , 27, 922-8	4.7	9
28	Pre-treatment diagnosis of endometrial cancer through a combination of CA125 and multiplication of neutrophil and monocyte. <i>Journal of Obstetrics and Gynaecology Research</i> , 2012 , 38, 48-56	1.9	12

27	Nanog signaling in cancer promotes stem-like phenotype and immune evasion. <i>Journal of Clinical Investigation</i> , 2012 , 122, 4077-93	15.9	131
26	Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years. <i>Journal of Korean Medical Science</i> , 2010 , 25, 1197-204	4.7	31
25	Prevalence and seroprevalence of high-risk human papillomavirus infection. <i>Obstetrics and Gynecology</i> , 2010 , 116, 932-940	4.9	9
24	The feasibility of carboplatin-based intraperitoneal chemotherapy in ovarian cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2010 , 152, 195-9	2.4	10
23	ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139. <i>International Journal of Oncology</i> , 2010 , 37, 399-412	4.4	17
22	Accuracy of preoperative tests in clinical stage I endometrial cancer: the importance of lymphadenectomy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2010 , 89, 175-81	3.8	20
21	The effects of polymorphisms in methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), and methionine synthase reductase (MTRR) on the risk of cervical intraepithelial neoplasia and cervical cancer in Korean women. <i>Cancer Causes and Control</i> , 2010 , 21, 23-30	2.8	15
20	Autoantibodies against stress-induced phosphoprotein-1 as a novel biomarker candidate for ovarian cancer. <i>Genes Chromosomes and Cancer</i> , 2010 , 49, 585-95	5	21
19	Treatment of the patients with abnormal cervical cytology: a "see-and-treat" versus three-step strategy. <i>Journal of Gynecologic Oncology</i> , 2009 , 20, 164-8	4	18
18	Relationship of serum antioxidant micronutrients and sociodemographic factors to cervical neoplasia: a case-control study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009 , 47, 1005-12	5.9	9
17	Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2009 , 57, 513-21	3.4	65
16	Functional polymorphism in manganese superoxide dismutase and antioxidant status: their interactions on the risk of cervical intraepithelial neoplasia and cervical cancer. <i>Gynecologic Oncology</i> , 2009 , 115, 272-6	4.9	21
15	Endometrial osteopontin mRNA expression and plasma osteopontin levels are increased in patients with endometriosis. <i>American Journal of Reproductive Immunology</i> , 2009 , 61, 286-93	3.8	37
14	Preoperative levels of plasma micronutrients are related to endometrial cancer risk. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2009 , 88, 434-9	3.8	6
13	Plasma carotenoids, retinol and tocopherol levels and the risk of ovarian cancer. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2009 , 88, 457-62	3.8	30
12	Multiplication of neutrophil and monocyte counts (MNM) as an easily obtainable tumour marker for cervical cancer. <i>Biomarkers</i> , 2009 , 14, 161-70	2.6	17
11	Diagnostic and prognostic impact of osteopontin expression in endometrial cancer. <i>Cancer Investigation</i> , 2009 , 27, 313-23	2.1	12
10	Molecular characterization of a new ovarian cancer cell line, YDOV-151, established from mucinous cystadenocarcinoma. <i>Tohoku Journal of Experimental Medicine</i> , 2009 , 218, 129-39	2.4	15

9	Surgical practice patterns in endometrial cancer: results of the Korean Gynecologic Oncology Group survey. <i>Journal of Gynecologic Oncology</i> , 2009 , 20, 107-12	4	15
8	Genomic and proteomic characterization of YDOV-157, a newly established human epithelial ovarian cancer cell line. <i>Molecular and Cellular Biochemistry</i> , 2008 , 319, 189-201	4.2	9
7	Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. <i>Clinical Cancer Research</i> , 2008 , 14, 764-71	12.9	49
6	Clinical approach and surgical strategy for spinal diseases in pregnant women: a report of ten cases. <i>Spine</i> , 2008 , 33, E614-9	3.3	49
5	Validation of a nomogram for predicting outcome of vulvar cancer patients, primarily treated by surgery, in Korean population: multicenter retrospective study through Korean Gynecologic Oncology Group (KGOG-1010). <i>Journal of Gynecologic Oncology</i> , 2008 , 19, 191-4	4	5
4	Clinical significance of microsatellite instability in sporadic epithelial ovarian tumors. <i>Yonsei Medical Journal</i> , 2008 , 49, 272-8	3	6
3	Osteopontin is down-regulated in hydatidiform mole. <i>Gynecologic Oncology</i> , 2003 , 89, 134-9	4.9	11
2	Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. <i>Clinical Cancer Research</i> , 2003 , 9, 4782-91	12.9	54
1	Osteopontin as a potential diagnostic biomarker for ovarian cancer. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 287, 1671-9	27.4	332